# ACELYRIN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acelyrin

- Industry: Biotechnology
- Headquarters: Agoura Hills, US
- Website: www.acelyrin.com
- Total disclosed funding: $550M
- Latest round: Series C (Sep 13, 2022)
- Investors on record: 13

## About

Based in California, US, and founded in 2020 by Shao-Lee Lin and Robert F. Carey, ACELYRIN, Inc. is a biopharma company that acquires, identifies, and accelerates the commercialization and development of drug therapies for patients with immunologic diseases. In May 2023, ACELYRIN, Inc. raised USD 540 million in an IPO, selling 30 million shares at USD 18 per share, on the Nasdaq Global Select Market under the ticker symbol SLRN.

The company is developing izokibep, which is a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor for the treatment of uveitis, axial spondyloarthritis, hidradenitis suppurativa (HS), and psoriatic arthritis.

## Funding rounds

- Series C, Sep 13, 2022, $300M — OrbiMed Advisors, Access Industries, Marshall Wace, Decheng Capital, VenBio, Cowen Investment Management, Samsara BioCapital, Surveyor Capital, Westlake Village BioPartners, Tybourne Capital Management, AyurMaya
- Series B, Oct 19, 2021, $250M — OrbiMed Advisors, Marshall Wace, Decheng Capital, VenBio, RTW Investments, Matrix Capital Management, Cowen Investment Management, Samsara BioCapital, Surveyor Capital, Westlake Village BioPartners, Tybourne Capital Management
- Series A, Dec 15, 2020 — Westlake Village BioPartners

## Investors

- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B, Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B, Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Matrix Capital Management — Series B
- Cowen Investment Management — Series B, Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B, Series C
- Surveyor Capital — Series B, Series C
- Tybourne Capital Management (https://capitalatlas.ai/funds/tybourne-capital-management) — Series B, Series C
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series C
- AyurMaya — Series C